Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Efficacy of Isatuximab in Chinese Patients with Relapsed/Refractory Multiple Myeloma
NCT03733717Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2018
- Primary completion
- Sep 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Started Oct 2018; status: completed.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03733717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733717.